Endothelial progenitor cell (EPC)-seeded intravascular stents

Cardiac Regeneration and Repair: Biomaterials and Tissue Engineering

Volumn , Issue , 2014, Pages 110-124

  Zhu, C ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Endothelial progenitor cells; Intravascular stents; Seeded; Slow release; Tissue engineering vessels

Indexed keywords

EID: 84903227191     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9780857096715.1.110     Document Type: Chapter

References (51)

1. Acharya G., Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev 2006, 58(3):387-401.
2. Alcocer A., Moreno R., Hernandez R., Perez-Vizcayno M.J., Conde C., et al. Clinical variables related with in-stent restenosis late regression after bare metal coronary stenting. Arch Cardiol Mex 2006, 76(4):390-396.
3. Anderson S.M., Chen T.T., Iruela-Arispe M.L., Segura T. The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF. Biomaterials 2009, 30(27):4618-4628.
4. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
5. Avci-Adali M., Ziemer G., Wendel H.P. Induction of EPC homing on biofunctionalized vascular grafts for rapid in vivo self-endothelialization - a review of current strategies. Biotechnol Adv 2010, 28(1):119-129.
6. Azzarelli S., Galassi A.R., Grosso G., Tomasello D., Campisano B., et al. Clinical and angiographic outcomes in elderly patients treated with endothelial progenitor cell capture coronary stents: results from a prospective single-center registry. J Invasive Cardiol 2010, 22(12):594-598.
7. Beijk M.A., Klomp M., Verouden N.J., van Geloven N., Koch K.T., et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J 2010, 31(9):1055-1064.
8. Brophy J.M., Belisle P., Joseph L. Evidence for use of coronary stents A hierarchical bayesian meta-analysis. Ann Intern Med 2003, 138(10):777-786.
9. Carter A.J., Aggarwal M., Kopia G.A., Tio F., Tsao P.S., et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004, 63(4):617-624.
10. Case J., Mead L.E., Bessler W.K., Prater D., White H.A., et al. Human CD34 + AC 133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35(7):1109-1118.
11. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108(7):788-794.
12. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369(9562):667-678.
13. Freyman T., Polin G., Osman H., Crary J., Lu M., et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006, 27(9):1114-1122.
14. Grines C.L., Bonow R.O., Casey D.E., Gardner T.J., Lockhart P.B., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007, 115(6):813-818.
15. Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003, 107(1):38-42.
16. Heil M., Ziegelhoeffer T., Mees B., Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004, 94(5):573-574.
17. Heublein B., Rohde R., Kaese V., Niemeyer M., Hartung W., Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. Heart 2003, 89(6):651-656.
18. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348(7):593-600.
19. Hoffmann J., Paul A., Harwardt M., Groll J., Reeswinkel T., et al. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J Biomed Mater Res A 2008, 84(3):614-621.
20. Hur J., Yoon C.H., Kim H.S., Choi J.H., Kang H.J., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24(2):288-293.
21. Klugherz B.D., Jones P.L., Cui X., Chen W., Meneveau N.F., et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000, 18(11):1181-1184.
22. Maluenda G., Lemesle G., Waksman R. A critical appraisal of the safety and efficacy of drug-eluting stents. Clin Pharmacol Ther 2009, 85(5):474-480.
23. Markway B.D., McCarty O.J., Marzec U.M., Courtman D.W., Hanson S.R., Hinds M.T. Capture of flowing endothelial cells using surface-immobilized anti-kinase insert domain receptor antibody. Tissue Eng Part C Methods 2008, 14(2):97-105.
24. Meredith I.T., Worthley S., Whitbourn R., Walters D.L., McClean D., et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009, 2(10):977-985.
25. Meredith I.T., Worthley S.G., Whitbourn R., Walters D., McClean D., et al. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. Eurolntervention 2010, 5(6):692-697.
26. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346(23):1773-1780.
27. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349(14):1315-1323.
28. Mukai N., Akahori T., Komaki M., Li Q., Kanayasu-Toyoda T., et al. A comparison of the tube forming potentials of early and late endothelial progenitor cells. Exp Cell Res 2008, 314(3):430-440.
29. Nakazawa G., Granada J.F., Alviar C.L., Tellez A., Kaluza G.L., et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010, 3(1):68-75.
30. Nordmann A.J., Briel M., Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006, 27(23):2784-2814.
31. Ong A.T., Aoki J., Kutryk M.J., Serruys P.W. How to accelerate the endothelialization of stents. Arch Mal Coeur Vaiss 2005, 98(2):123-126.
32. Palmerini T., Biondi-Zoccai G., Della Riva D., Stettler C., Sangiorgi D., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379(9824):1393-1402.
33. + cells identifies a population of functional endothelial precursors. Blood 2000, 95(3):952-958.
34. Pislaru S.V., Harbuzariu A., Agarwal G., Witt T., Gulati R., et al. Magnetic forces enable rapid endothelialization of synthetic vascular grafts. Circulation 2006, 114(1 Suppl):I314-I318.
35. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., et al. Executive summary: heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125(1):188-197.
36. Rotmans J.I., Heyligers J.M., Verhagen H.J., Velema E., Nagtegaal M.M., et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 2005, 112(1):12-18.
37. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350(3):221-231.
38. Suuronen E.J., Veinot J.P., Wong S., Kapila V., Price J., et al. Tissue-engineered injectable collagen-based matrices for improved cell delivery and vascularization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood. Circulation 2006, 114(1 Suppl):1138-1144.
39. Suuronen E.J., Zhang P., Kuraitis D., Cao X., Melhuish A., et al. An acellular matrix-bound ligand enhances the mobilization, recruitment and therapeutic effects of circulating progenitor cells in a hindlimb ischemia model. FASEB J 2009, 23(5):1447-1458.
40. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5(4):434-438.
41. Tanabe K., Serruys P.W., Degertekin M., Guagliumi G., Grube E., et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004, 109(2):196-200.
42. Veleva A.N., Heath D.E., Cooper S.L., Patterson C. Selective endothelial cell attachment to peptide-modified terpolymers. Biomaterials 2008, 29(27):3656-3661.
43. Waksman R., Pakala R., Kuchulakanti P.K., Baffour R., Hellinga D., et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006, 68(4):607-617. discussion 618-19.
44. Walter D.H., Cejna M., Diaz-Sandoval L., Willis S., Kirkwood L., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004, 110(1):36-45.
45. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105(25):3017-3024.
46. Wendel H.P., Avci-Adali M., Ziemer G. Endothelial progenitor cell capture stents--hype or hope?. Int J Cardiol 2010, 145(1):115-117. author reply 117-18.
47. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90(12):5002-5012.
48. Yoon C.H., Hur J., Park K.W., Kim J.H., Lee C.S., et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005, 112(11):1618-1627.
49. Zampetaki A., Kirton J.P., Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008, 78(3):413-421.
50. Zeng W., Wen C., Wu Y., Li L., Zhou Z., et al. The use of BDNF to enhance the patency rate of small-diameter tissue-engineered blood vessels through stem cell homing mechanisms. Biomaterials 2012, 33(2):473-484.
51. Zeng W., Yuan W., Li L., Mi J., Xu S., et al. The promotion of endothelial progenitor cells recruitment by nerve growth factors in tissue-engineered blood vessels. Biomaterials 2010, 31(7):1636-1645.